Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

03 June 2004 : Original article  

How about the effect of thiazolidinediones in diabetic nephropathy?

Keisuke Ina

Med Sci Monit 2004; 10(6): LE7-7 :: ID: 16409

Abstract

Dear Editor, The metabolic effects of insulin and rosiglitazone combination therapy in Chinese Type 2 diabetic patients with nephropathy I am afraid that thiazolidinedione (TZD) could not stastically ameliorate lipid metabolism in type 2 diabetic patients with nephropathy. As to the effect of TZD on diabetic nephropathy, I would like to offer a comment. It has been reported that TZD had the renoprotective effect, containing attenuation of glomerular hyperfiltration and decrease of urinary albumin excretion rate(UAE) in experimental diabetic rats as well as diabetic patients [1–3], as the author would mention in the present article. Recently, the mechanism by which TZD improved renal dysfunction was determined [2,4]. TZD was indicated to have the renoprotective effect through inhibiting activation of DAG-PKC-ERK pathway which leaded to renal dysfunction in diabetes. In previous reports, it has been shown that TZD ameliorated microalbuminuria, treated with TZD only or TZD and the angiotensin converting enzyme inhibitor [1–3]. The feature of cases in the present paper is, first, that the degree of nephropathy was moderate or severe, although the level of UAE and the value of glomerular filtration rate were not shown. Second, the angiotensin II receptor blocker (ARB) was treated in all of the patients before combination therapy with TZD. I should like to know the effect of ARB and TZD combination therapy on moderate or severe diabetic nephropathy. The effects of TZD on other organs as well as the fat tissue and the kidney are expected.

Keywords: Albumins - analysis, Diabetic Nephropathies - complications, Diabetic Nephropathies - drug therapy, Diabetic Nephropathies - metabolism, Kidney Diseases - complications, Kidney Diseases - drug therapy, Kidney Diseases - metabolism, Lipid Metabolism, Thiazolidinediones - pharmacology, Thiazolidinediones - therapeutic use, Albumins - analysis, Diabetic Nephropathies - metabolism, Kidney Diseases - metabolism, Lipid Metabolism, Thiazolidinediones - therapeutic use

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750